tiprankstipranks
Trending News
More News >
Enzo Biochem (ENZ)
NYSE:ENZ

Enzo Biochem (ENZ) AI Stock Analysis

Compare
187 Followers

Top Page

EN

Enzo Biochem

(NYSE:ENZ)

47Neutral
Enzo Biochem's overall stock score reflects significant financial and operational challenges, including negative profitability, poor technical performance, and an unfavorable valuation. The decision to delist from the NYSE adds to the uncertainty surrounding the stock. These factors collectively suggest a cautious outlook, necessitating strategic improvements for future stability.

Enzo Biochem (ENZ) vs. S&P 500 (SPY)

Enzo Biochem Business Overview & Revenue Model

Company DescriptionEnzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
How the Company Makes MoneyEnzo Biochem generates revenue primarily through its two operational segments. The Enzo Clinical Labs segment earns income by providing diagnostic testing services to physicians, medical centers, and other healthcare facilities. This segment is a key revenue driver due to the high volume of tests it conducts, which includes both routine and specialized testing services. The Enzo Life Sciences segment, on the other hand, generates revenue through the sale of life science research products and tools that include antibodies, proteins, assays, and small molecules. This segment caters to a global market of academic and government institutions, biotechnology and pharmaceutical companies. Enzo Biochem's revenue model is supported by its proprietary technologies and strategic partnerships, which enhance its capabilities in product development and distribution.

Enzo Biochem Financial Statement Overview

Summary
Enzo Biochem faces considerable financial challenges, with declining revenues, negative profit margins, and cash flow difficulties. The balance sheet shows low leverage and substantial equity, but persistent losses and cash flow issues present significant risks.
Income Statement
45
Neutral
Enzo Biochem's income statement shows significant challenges with profitability. The TTM (Trailing-Twelve-Months) data indicates a negative gross profit margin of 45.6%, a net profit margin of -73.2%, and declining revenue trends. The company has struggled to maintain positive EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to revenue.
Balance Sheet
60
Neutral
The balance sheet reveals moderate financial stability. Enzo Biochem has a low debt-to-equity ratio of 0.06, indicating low financial leverage. The equity ratio stands at 69%, which is a positive sign of financial health. However, the return on equity (ROE) is negative due to ongoing losses, which could deter potential investors.
Cash Flow
50
Neutral
The cash flow statement highlights cash flow issues, with negative operating and free cash flows in the TTM (Trailing-Twelve-Months). The company struggles with cash generation, as evidenced by the negative free cash flow to net income ratio. However, cash reserves remain substantial, which could help mitigate short-term liquidity risks.
Breakdown
TTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
29.09M31.91M31.06M107.07M117.73M76.02M
Gross Profit
13.27M14.63M11.57M41.97M53.58M23.77M
EBIT
-8.69M-9.82M-24.74M-15.51M9.88M-23.64M
EBITDA
-7.36M-8.35M-20.94M-15.01M3.35M-27.59M
Net Income Common Stockholders
-21.31M-26.08M20.29M-22.58M3.42M-33.89M
Balance SheetCash, Cash Equivalents and Short-Term Investments
31.56M52.37M82.37M21.60M43.50M47.87M
Total Assets
115.45M85.76M121.88M95.86M113.69M112.54M
Total Debt
0.003.51M7.00M20.59M22.68M32.79M
Net Debt
-8.75M-48.86M-75.38M-1.02M9.15M-15.07M
Total Liabilities
18.52M29.65M43.42M41.40M45.10M54.16M
Stockholders Equity
96.92M56.11M78.46M54.46M68.59M58.38M
Cash FlowFree Cash Flow
-15.75M-26.80M-39.74M-20.06M-4.05M-19.35M
Operating Cash Flow
-14.96M-26.26M-36.98M-16.59M387.00K-17.18M
Investing Cash Flow
4.22M-545.00K98.98M25.22M-34.50M-2.17M
Financing Cash Flow
-9.18M-4.19M-1.13M-241.00K-242.00K7.00M

Enzo Biochem Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.40
Price Trends
50DMA
0.44
Negative
100DMA
0.61
Negative
200DMA
0.82
Negative
Market Momentum
MACD
-0.03
Negative
RSI
52.54
Neutral
STOCH
39.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZ, the sentiment is Neutral. The current price of 0.4 is above the 20-day moving average (MA) of 0.35, below the 50-day MA of 0.44, and below the 200-day MA of 0.82, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 52.54 is Neutral, neither overbought nor oversold. The STOCH value of 39.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ENZ.

Enzo Biochem Risk Analysis

Enzo Biochem disclosed 30 risk factors in its most recent earnings report. Enzo Biochem reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Enzo Biochem Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$5.20B3.26-40.34%2.93%17.68%1.94%
ENENZ
47
Neutral
$16.77M-12.94%
46
Neutral
$182.34M-270.01%-65.96%40.80%
IGIGC
45
Neutral
$22.79M-115.06%1.64%50.63%
36
Underperform
$19.57M-55.95%32.42%
35
Underperform
$20.21M-164.30%44.38%
28
Underperform
$25.43M-2880.11%24.35%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ENZ
Enzo Biochem
0.45
-0.52
-53.61%
IGC
IGC Pharma
0.29
-0.15
-34.09%
TVRD
Tvardi Therapeutics
18.48
-5.70
-23.57%
ENLV
Enlivex
0.92
-0.58
-38.67%
BCAB
BioAtla
0.38
-1.97
-83.83%
NRSN
Neurosense Therapeutics Ltd.
0.99
-0.35
-26.12%

Enzo Biochem Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Enzo Biochem to Delist from NYSE, Move to OTCQX
Negative
Mar 31, 2025

On March 28, 2025, Enzo Biochem announced its decision to voluntarily delist its common stock from the New York Stock Exchange (NYSE) and move to the OTCQX Best Market. This strategic shift follows a notice from the NYSE regarding non-compliance with listing standards related to market capitalization, stockholder’s equity, and average closing stock price. The company plans for the delisting to be effective around April 17, 2025, with trading on OTCQX expected to begin on April 18, 2025. Enzo Biochem aims to ensure a smooth transition for shareholders, maintaining electronic trading without disruption and continuing to meet periodic reporting requirements under the Securities Exchange Act of 1934.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.